drugset / Trial / NCT05551247
Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The objective is to investigate the efficacy and safety of envafolimab combined with recombinant human endostatin (endostatin) in the treatment of MSS-type colorectal cancer patients with recurrence or metastasis after failure of second-line standard therapy.
Timeline
- Start
- 2022-09-15
- Primary completion
- 2023-06-28
- Completion
- 2024-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 210 mg | Intravenous |
| Subject | Envafolimab | Monoclonal antibody | 300 mg | Subcutaneous |